BRKR vs TXG: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BRKR and TXG are similarly sized, but BRKR trades noticeably cheaper on forward earnings (26.14x vs 731.16x): the market is paying up for TXG's profile and pricing BRKR more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.

BRKR vs TXG: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBRKRTXGWhat it tells you
Market cap$9.78B$8.34BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E26.14731.16Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.272.03Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range87% of range55% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.289.94How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: BRKR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how BRKR and TXG affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BRKR and TXG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BRKR and TXG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Bruker Corporation (BRKR) do?

Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. It operates through four segments: BioSpin (nuclear magnetic resonance spectroscopy and preclinical imaging), CALID (mass spectrometry and chromatography for life-science and applied markets), Nano (surface analysis and microscopy including atomic force microscopy), and BEST (superconducting magnets and X-ray detectors). The company is a recognized leader in specialized, complex applications such as structural biology, proteomics, and advanced materials, competing in what is effectively a duopoly with Thermo Fisher in high-end NMR and mass spectrometry.

Full BRKR guide

What does 10x Genomics (TXG) do?

10x Genomics, Inc. (Nasdaq: TXG) builds instruments, reagents, and software for single-cell and spatial biology, the tools scientists use to read gene activity one cell at a time and map it across intact tissue. Its core franchises are Chromium (single-cell analysis), the Visium and Xenium spatial platforms, and the newly launched Atera in situ system (list price around $495,000, shipping in the second half of 2026). Revenue skews toward recurring consumables sold to academic labs, pharma and biotech research groups, and core genomics facilities, with instrument placements driving the razor-and-blade model over time.

Full TXG guide

BRKR vs TXG: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • BRKR drivers: High-end instruments moat; Adjacent growth vectors.
  • TXG drivers: Consumables-led recurring revenue; New platform launches (Atera and spatial).

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. For TXG, the biggest overhang is demand: U.S.

BRKR or TXG: which should you pick?

Pick BRKR if you believe its drivers more; TXG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BRKR and TXG guides.

BRKR vs TXG: the full fundamentals

BRKR. Bruker beat EPS estimates in Q1 2026 (~$0.31 versus ~$0.23) and again in Q2 (~$0.49 versus ~$0.38), even as GAAP results stayed negative. The rally of the past year has lifted the forward multiple to roughly 23x, higher than the 15x to 16x it carried in mid-2026, which leaves less cushion if the expected fourth-quarter rebound in research and semiconductor demand comes in light. The average analyst target is about $63.83 from 12 analysts, though JPMorgan's October downgrade set $60.

TXG. 10x Genomics trades at roughly 15x sales while revenue is essentially flat and the company still runs a net loss, so the market is paying for future growth rather than current profits; the multiple has roughly doubled since mid-2026. Consensus for the September quarter, due November 5, 2026, is about $148M of revenue and an adjusted loss of $0.02 per share. The key swing factor remains whether academic and biopharma spending thaws, and Atera orders build, enough to restart instrument placements.

Headline figures (approximate, October 2026): BRKR shows revenue (ttm) ~$3.5B; Q2 2026 revenue ~$838.5M, up ~5.2% YoY, q2 2026 non-gaap eps ~$0.49 vs ~$0.38 consensus, margins Gross ~48.5%, operating ~9.9%; GAAP net margin ~-2% after restructuring and acquisition charges, fy2026 consensus Revenue ~$3.56B, non-GAAP EPS ~$2.12 (prior guidance ~$2.10 to $2.15); TXG shows revenue (ttm) ~$617M, q2 2026 revenue ~$151M (~-13% YoY vs a settlement-boosted prior year), gross / operating margin ~70% / ~-15%, net income (ttm) ~-$75M.

The bottom line: BRKR vs TXG

BRKR and TXG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BRKR and TXG exposure against your real portfolio. It is not an investment adviser.

Wondering how BRKR or TXG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Bruker Corporation

Ask Walnut's AI anything about BRKR and see how it fits what you own.

FAQ

What is the difference between BRKR and TXG?

+

Bruker Corporation designs and sells high-performance scientific instruments used in research, life sciences, materials science, and industrial applications. 10x Genomics, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BRKR or TXG the better stock?

+

Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BRKR or TXG?

+

On forward P/E (as of November 2026), BRKR trades at 26.14x and TXG at 731.16x, so BRKR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BRKR and TXG?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BRKR vs TXG?

+

BRKR: Bruker's largest customers are academic, government, and pharmaceutical research labs, so cuts to U.S. and international research funding directly pressure demand, and organic revenue has been declining as a result. The company flagged an approximately $100 million revenue headwind and $90 million operating-profit impact tied to academic funding disruptions. Heavy acquisition activity introduces integration risk and can mask organic softness, while a large, more diversified competitor in Thermo Fisher can outspend Bruker across the portfolio. Supply-chain exposure to items like high-performance memory chips and liquid helium, plus U.S.-China trade and geopolitical tensions, add further uncertainty. Turning frontier technologies into repeatable, high-volume commercial revenue remains an ongoing execution challenge. Near term, the full-year numbers depend on a large fourth quarter (consensus near $1.03 billion of revenue versus about $838.5 million in the second quarter), so any slip in that rebound would land directly on guidance. Leverage has also risen with acquisitions, to about $1.86 billion of debt against roughly $185 million of cash. TXG: The biggest overhang is demand: U.S. academic and NIH-linked research funding plus biopharma capital budgets have tightened sharply, and instrument sales dropped about 24% year over year, driving management's flat guidance. The company is still unprofitable on a net basis (about -$75M over the trailing twelve months), so the valuation, now near 15x sales after a 318% gain in 2026, leans heavily on a growth reacceleration that may not arrive on schedule. Consensus still expects 2026 revenue of only about $621M and 2027 revenue of about $684M. The stock is extremely volatile: its 52-week range runs from about $11.81 to $102.81, and it fell about 9% over the month to October 16. Competition is intensifying from Illumina, Bruker Spatial, Bio-Techne, Akoya, Vizgen, Bio-Rad, and newer single-cell entrants, and 10x has a long history of patent litigation whose settlements produced non-recurring revenue that will not repeat. New-platform adoption (Atera) is unproven at scale, and results can be lumpy quarter to quarter.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BRKR or TXG; figures are approximate and dated (as of November 2026). Verify current data before investing.